|
1
|
Lan C, Chenggang W, Yulan B, Xiaohui D,
Junhui Z and Xiao W: Aberrant expression of WWOX protein in
epithelial ovarian cancer: a clinicopathologic and
immunohistochemical study. Int J Gynecol Pathol. 31:125–132. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Vlahovic G, Meadows KL, Uronis HE, et al:
A phase I study of bevacizumab, everolimus and panitumumab in
advanced solid tumors. Cancer Chemother Pharmacol. 70:95–102. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Hennessy BT, Coleman RL and Markman M:
Ovarian cancer. Lancet. 374:1371–1382. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lin S, Zhang H, Han T, Wu JZ, Rahman K and
Qin LP: In vivo effect of casticin on acute inflammation. Zhong Xi
Yi Jie He Xue Bao. 5:573–576. 2007. View Article : Google Scholar
|
|
5
|
Li WX, Cui CB, Cai B, Wang HY and Yao XS:
Flavonoids from Vitex trifolia Linhibit cell cycle
progression at G2/M phase and induce apoptosis in mammalian cancer
cells. J Asian Nat Prod Res. 7:615–626. 2005.
|
|
6
|
Chen D, Cao J, Tian L, Liu F and Sheng X:
Induction of apoptosis by casticin in cervical cancer cells through
reactive oxygen species-mediated mitochondrial signaling pathways.
Oncol Rep. 26:1287–1294. 2011.PubMed/NCBI
|
|
7
|
Zeng F, Tian L, Liu F, Cao J, Quan M and
Sheng X: Induction of apoptosis by casticin in cervical cancer
cells: reactive oxygen species-dependent sustained activation of
Jun N-terminal kinase. Acta Biochim Biophys Sin (Shanghai).
44:442–449. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Díaz F, Chávez D, Lee D, et al: Cytotoxic
flavone analogues of vitexicarpin, a constituent of the leaves of
Vitex negundo. J Nat Prod. 66:865–867. 2003.PubMed/NCBI
|
|
9
|
Haïdara K, Zamir L, Shi QW and Batist G:
The flavonoid Casticin has multiple mechanisms of tumor
cytotoxicity action. Cancer Lett. 242:180–190. 2006.PubMed/NCBI
|
|
10
|
Imai M, Kikuchi H, Denda T, Ohyama K,
Hirobe C and Toyoda H: Cytotoxic effects of flavonoids against a
human colon cancer derived cell line, COLO 201: a potential natural
anti-cancer substance. Cancer Lett. 276:74–80. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Yang J, Yang Y, Tian L, Sheng XF, Liu F
and Cao JG: Casticin-induced apoptosis involves death receptor 5
upregulation in hepatocellular carcinoma cells. World J
Gastroenterol. 17:4298–4307. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Hernández MM, Heraso C, Villarreal ML,
Vargas-Arispuro I and Aranda E: Biological activities of crude
plant extracts from Vitex trifolia L. (Verbenaceae). J
Ethnopharmacol. 67:37–44. 1999.
|
|
13
|
Hannenhalli S and Kaestner KH: The
evolution of Fox genes and their role in development and disease.
Nat Rev Genet. 10:233–240. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
14
|
Korver W, Roose J and Clevers H: The
winged-helix transcription factor Trident is expressed in cycling
cells. Nucleic Acids Res. 25:1715–1719. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kwok JM, Peck B, Monteiro LJ, et al: FOXM1
confers acquired cisplatin resistance in breast cancer cells. Mol
Cancer Res. 8:24–34. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Bergamaschi A, Christensen BL and
Katzenellenbogen BS: Reversal of endocrine resistance in breast
cancer: interrelationships among 14-3-3ζ, FOXM1, and a gene
signature associated with mitosis. Breast Cancer Res.
13:R702011.PubMed/NCBI
|
|
17
|
Feo F, Frau M and Pascale RM: Interaction
of major genes predisposing to hepatocellular carcinoma with genes
encoding signal transduction pathways influences tumor phenotype
and prognosis. World J Gastroenterol. 14:6601–6615. 2008.
View Article : Google Scholar
|
|
18
|
Chen W, Yuan K, Tao ZZ and Xiao BK:
Deletion of Forkhead Box M1 transcription factor reduces malignancy
in laryngeal squamous carcinoma cells. Asian Pac J Cancer Prev.
12:1785–1788. 2011.PubMed/NCBI
|
|
19
|
Halasi M and Gartel AL: Suppression of
FOXM1 sensitizes human cancer cells to cell death induced by
DNA-damage. PLoS One. 7:e317612012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wonsey DR and Follettie MT: Loss of the
forkhead transcription factor FoxM1 causes centrosome amplification
and mitotic catastrophe. Cancer Res. 65:5181–5189. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Down CF, Millour J, Lam EW and Watson RJ:
Binding of FoxM1 to G2/M gene promoters is dependent upon B-Myb.
Biochim Biophys Acta. 1819:855–862. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Millour J, de Olano N, Horimoto Y, et al:
ATM and p53 regulate FOXM1 expression via E2F in breast cancer
epirubicin treatment and resistance. Mol Cancer Ther. 10:1046–1058.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Schüller U, Zhao Q, Godinho SA, et al:
Forkhead transcription factor FoxM1 regulates mitotic entry and
prevents spindle defects in cerebellar granule neuron precursors.
Mol Cell Biol. 27:8259–8270. 2007.PubMed/NCBI
|
|
24
|
Fu Z, Malureanu L, Huang J, et al:
PLK1-dependent phosphorylation of FoxM1 regulates a transcriptional
programme required for mitotic progression. Nat Cell Biol.
10:1076–1082. 2008. View
Article : Google Scholar : PubMed/NCBI
|
|
25
|
Laoukili J, Alvarez-Fernandez M, Stahl M
and Medema RH: FoxM1 is degraded at mitotic exit in a
Cdh1-dependent manner. Cell Cycle. 7:2720–2726. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Delpuech O, Griffiths B, East P, et al:
Induction of Mxi1-SR alpha by FOXO3a contributes to repression of
Myc-dependent gene expression. Mol Cell Biol. 27:4917–4930. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
McGovern UB, Francis RE, Peck B, et al:
Gefitinib (Iressa) represses FOXM1 expression via FOXO3a in breast
cancer. Mol Cancer Ther. 8:582–591. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wilson MS, Brosens JJ, Schwenen HD and Lam
EW: FOXO and FOXM1 in cancer: the FOXO-FOXM1 axis shapes the
outcome of cancer chemotherapy. Curr Drug Targets. 12:1256–1266.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Fang L, Wang H, Zhou L and Yu D:
Akt-FOXO3a signaling axis dysregulation in human oral squamous cell
carcinoma and potent efficacy of FOXO3a-targeted gene therapy. Oral
Oncol. 47:16–21. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Lam M, Carmichael AR and Griffiths HR: An
aqueous extract of Fagonia cretica induces DNA damage, cell
cycle arrest and apoptosis in breast cancer cells via FOXO3a and
p53 expression. PLoS One. 7:e401522012.PubMed/NCBI
|
|
31
|
Yusuf I, Zhu X, Kharas MG, Chen J and
Fruman DA: Optimal B-cell proliferation requires phosphoinositide
3-kinase-dependent inactivation of FOXO transcription factors.
Blood. 104:784–787. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Wang Z, Ahmad A, Banerjee S, et al: FoxM1
is a novel target of a natural agent in pancreatic cancer. Pharm
Res. 27:1159–1168. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Ning Y, Li Q, Xiang H, Liu F and Cao J:
Apoptosis induced by 7-difluoromethoxyl-5,4’-di-n-octyl genistein
via the inactivation of FoxM1 in ovarian cancer cells. Oncol Rep.
27:1857–1864. 2012.PubMed/NCBI
|
|
34
|
Bellelli R, Castellone MD, Garcia-Rostan
G, et al: FOXM1 is a molecular determinant of the mitogenic and
invasive phenotype of anaplastic thyroid carcinoma. Endocr Relat
Cancer. 19:695–710. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Dibb M, Han N, Choudhury J, et al: The
FOXM1-PLK1 axis is commonly upregulated in oesophageal
adenocarcinoma. Br J Cancer. 107:1766–1775. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Ha SY, Lee CH, Chang HK, et al:
Differential expression of forkhead box M1 and its downstream
cyclin-dependent kinase inhibitors p27(kip1) and p21(waf1/cip1) in
the diagnosis of pulmonary neuroendocrine tumours. Histopathology.
60:731–739. 2012. View Article : Google Scholar
|
|
37
|
Cancer Genome Atlas Research Network:
Integrated genomic analyses of ovarian carcinoma. Nature.
474:609–615. 2011. View Article : Google Scholar
|
|
38
|
Petrovic V, Costa RH, Lau LF, Raychaudhuri
P and Tyner AL: FoxM1 regulates growth factor-induced expression of
kinase-interacting stathmin (KIS) to promote cell cycle
progression. J Biol Chem. 283:453–460. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Kwok JM, Myatt SS, Marson CM, Coombes RC,
Constantinidou D and Lam EW: Thiostrepton selectively targets
breast cancer cells through inhibition of forkhead box M1
expression. Mol Cancer Ther. 7:2022–2032. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Petrovic V, Costa RH, Lau LF, Raychaudhuri
P and Tyner AL: Negative regulation of the oncogenic transcription
factor FoxM1 by thiazolidinediones and mithramycin. Cancer Biol
Ther. 9:1008–1016. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Roy SK, Srivastava RK and Shankar S:
Inhibition of PI3K/AKT and MAPK/ERK pathways causes activation of
FOXO transcription factor, leading to cell cycle arrest and
apoptosis in pancreatic cancer. J Mol Signal. 5:102010. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Zanella F, Link W and Carnero A:
Understanding FOXO, new views on old transcription factors. Curr
Cancer Drug Targets. 10:135–146. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Myatt SS and Lam EW: The emerging roles of
forkhead box (Fox) proteins in cancer. Nat Rev Cancer. 7:847–859.
2007. View Article : Google Scholar : PubMed/NCBI
|
